Form 4: Capricor Therapeutics Director David B. Musket Acquires Stock Options
SEC Form 4 Filing
Director David B. Musket of Capricor Therapeutics acquired stock options for 24,170 shares on January 2, 2025, as part of his annual board service and committee service.
Summary
- David B. Musket, a director at Capricor Therapeutics, acquired stock options for a total of 24,170 shares on January 2, 2025.
- These options are divided into three grants: 11,940 shares related to annual board service, 6,480 shares for annual board committee service, and 5,750 shares for annual board service.
- The options have an exercise price of $14.96 per share and expire on January 2, 2035.
- The 11,940 share option grant vests monthly starting February 1, 2025, and ending December 31, 2025.
- The other two grants of 6,480 and 5,750 shares are fully vested and exercisable as of the grant date, January 2, 2025.
Sentiment
Score: 7
Explanation: The document reflects a standard practice of stock option grants to a director, which is generally viewed positively as it aligns interests. There are no negative implications.
Positives
- The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.
- The vesting schedule for part of the options aligns the director's interests with the company's performance over the next year.
Industry Context
Stock option grants to directors are a common practice in the biotechnology industry to align the interests of management with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for board members across the biotechnology industry.
- The vesting schedule of the 11,940 options is typical for annual board service grants, often vesting over a one-year period.
- The immediate vesting of the other options is also common for committee service and other specific contributions.
Stakeholder Impact
- The stock option grants may have a minor positive impact on shareholder sentiment as it indicates the director's commitment to the company.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the stock option grants and the date the fully vested options become exercisable. |
| 02/01/2025 | Start date for monthly vesting of 11,940 stock options. |
| 12/31/2025 | End date for monthly vesting of 11,940 stock options. |
| 01/02/2035 | Expiration date of all stock options. |
| 01/06/2025 | Date the form was signed. |
Keywords
stock options, director, Capricor Therapeutics, insider trading, equity, compensation, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.